Journal Watch · The New England Journal of Medicine · 2026

Group B Streptococcal Disease.

Vaccines against group B streptococcal disease that consist of capsular polysaccharides linked to protein antigens are in development and may provide a means of prevention for all at-risk populations.

Puopolo KMThe New England Journal of Medicine3 min readPharma relevance 50/100

DOI: 10.1056/nejmra2313146PMID: 41740033Study type: research study

TL;DR

Vaccines against group B streptococcal disease that consist of capsular polysaccharides linked to protein antigens are in development and may provide a means of prevention for all at-risk populations.

Key findings

  • No strategies are currently available to prevent disease in later infancy or among nonpregnant adults.
  • Vaccines against group B streptococcal disease that consist of capsular polysaccharides linked to protein antigens are in development and may provide a means of prevention for all at-risk populations.

What they did

Intrapartum antibiotic prophylaxis is currently used to reduce the risk of group B streptococcal disease among pregnant persons and newborns.

Full abstract (original)

Background: Group B streptococcus commonly colonizes the human gastrointestinal and genitourinary tracts and is the single most common bacterial cause of invasive infection among newborns in the United States.

What they did: Intrapartum antibiotic prophylaxis is currently used to reduce the risk of group B streptococcal disease among pregnant persons and newborns.

Results & conclusions: No strategies are currently available to prevent disease in later infancy or among nonpregnant adults. Vaccines against group B streptococcal disease that consist of capsular polysaccharides linked to protein antigens are in development and may provide a means of prevention for all at-risk populations.

Abstract © the authors / The New England Journal of Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1056/nejmra2313146 · PubMed 41740033.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this The New England Journal of Medicine study find?

Vaccines against group B streptococcal disease that consist of capsular polysaccharides linked to protein antigens are in development and may provide a means of prevention for all at-risk populations.

What type of study is this?

It is a research study, published in The New England Journal of Medicine in 2026. Intrapartum antibiotic prophylaxis is currently used to reduce the risk of group B streptococcal disease among pregnant persons and newborns.

Where can I read the original paper?

The original is at the publisher via DOI 10.1056/nejmra2313146. PubMed ID: 41740033. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Puopolo KM. Group B Streptococcal Disease.. The New England Journal of Medicine (2026). DOI: 10.1056/nejmra2313146.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/group-b-streptococcal-disease-313146/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides